OBJECTIVE: CCR5 and its ligands (CCL3, CCL4, and CCL5) may play a role in inflammatory cell recruitment into the joint. However, it was recently reported that CCR5 on T cells and neutrophils acts as a decoy receptor for CCL3 and CCL5 to assist in the resolution of inflammation. The aim of this study was to determine whether CCR5 functions as a proinflammatory or antiinflammatory mediator in arthritis, by examining the role of CCR5 in proteoglycan (PG)-induced arthritis (PGIA). METHODS: Arthritis was induced by immunizing wild-type (WT) and CCR5-deficient (CCR5(-/-)) BALB/c mice with human PG in adjuvant. The onset and severity of PGIA were monitored over time. Met-RANTES was used to block CCR5 in vivo. Arthritis was transferred to SCID mice, using spleen cells from arthritic WT and CCR5(-/-) mice. The expression of cytokines and chemokines was measured by enzyme-linked immunosorbent assay. RESULTS: In CCR5(-/-) mice and WT mice treated with the CCR5 inhibitor Met-RANTES, exacerbated arthritis developed late in the disease course. The increase in arthritis severity in CCR5(-/-) mice correlated with elevated serum levels of CCL5. However, exacerbated arthritis was not intrinsic to the CCR5(-/-) lymphoid cells, because the arthritis that developed in SCID mouse recipients was similar to that in WT and CCR5(-/-) mice. CCR5 expression in the SCID mouse was sufficient to clear CCL5, because serum levels of CCL5 were the same in SCID mouse recipients receiving cells from either WT or CCR5(-/-) mice. CONCLUSION: These data demonstrate that CCR5 is a key player in controlling the resolution of inflammation in experimental arthritis.
OBJECTIVE:CCR5 and its ligands (CCL3, CCL4, and CCL5) may play a role in inflammatory cell recruitment into the joint. However, it was recently reported that CCR5 on T cells and neutrophils acts as a decoy receptor for CCL3 and CCL5 to assist in the resolution of inflammation. The aim of this study was to determine whether CCR5 functions as a proinflammatory or antiinflammatory mediator in arthritis, by examining the role of CCR5 in proteoglycan (PG)-induced arthritis (PGIA). METHODS:Arthritis was induced by immunizing wild-type (WT) and CCR5-deficient (CCR5(-/-)) BALB/c mice with humanPG in adjuvant. The onset and severity of PGIA were monitored over time. Met-RANTES was used to block CCR5 in vivo. Arthritis was transferred to SCIDmice, using spleen cells from arthritic WT and CCR5(-/-) mice. The expression of cytokines and chemokines was measured by enzyme-linked immunosorbent assay. RESULTS: In CCR5(-/-) mice and WTmice treated with the CCR5 inhibitor Met-RANTES, exacerbated arthritis developed late in the disease course. The increase in arthritis severity in CCR5(-/-) mice correlated with elevated serum levels of CCL5. However, exacerbated arthritis was not intrinsic to the CCR5(-/-) lymphoid cells, because the arthritis that developed in SCIDmouse recipients was similar to that in WT and CCR5(-/-) mice. CCR5 expression in the SCIDmouse was sufficient to clear CCL5, because serum levels of CCL5 were the same in SCIDmouse recipients receiving cells from either WT or CCR5(-/-) mice. CONCLUSION: These data demonstrate that CCR5 is a key player in controlling the resolution of inflammation in experimental arthritis.
Authors: Christian A Wysocki; Qi Jiang; Angela Panoskaltsis-Mortari; Patricia A Taylor; Karen P McKinnon; Lishan Su; Bruce R Blazar; Jonathan S Serody Journal: Blood Date: 2005-07-07 Impact factor: 22.113
Authors: Christophe Moreno; Thierry Gustot; Charles Nicaise; Eric Quertinmont; Nathalie Nagy; Marc Parmentier; Olivier Le Moine; Jacques Devière; Hubert Louis Journal: Hepatology Date: 2005-10 Impact factor: 17.425
Authors: J J Gómez-Reino; J L Pablos; P E Carreira; B Santiago; L Serrano; J L Vicario; A Balsa; M Figueroa; M D de Juan Journal: Arthritis Rheum Date: 1999-05
Authors: P Garred; H O Madsen; J Petersen; H Marquart; T M Hansen; S Freiesleben Sørensen; B Volck; A Svejgaard; V Andersen Journal: J Rheumatol Date: 1998-08 Impact factor: 4.666
Authors: B Moradi; N Rosshirt; E Tripel; J Kirsch; A Barié; F Zeifang; T Gotterbarm; S Hagmann Journal: Clin Exp Immunol Date: 2015-04 Impact factor: 4.330
Authors: Vitor H Pomin; Younghee Park; Rongrong Huang; Christian Heiss; Joshua S Sharp; Parastoo Azadi; James H Prestegard Journal: Glycobiology Date: 2012-02-17 Impact factor: 4.313
Authors: Carlos Eduardo Repeke; Samuel Barros Ferreira; Andreia Espindola Vieira; Elcia Maria Silveira; Mario Julio Avila-Campos; João Santana da Silva; Carlos Ferreira Santos; Ana Paula Campanelli; Ana Paula Favaro Trombone; Gustavo Pompermaier Garlet Journal: PLoS One Date: 2011-07-20 Impact factor: 3.240